header-10.jpg
About Us

Jennifer Gunter

Jennifer Gunter

Positions

  • Postdoctoral Research Fellow (Cancer Metabolism), APCRC-Q
  • Research Fellow, Cure Cancer/Movember PCFA Young Investigator
  • Member, IHBI, QUT

Contact Details

Phone
+61 7 3443 7337
Linkedin profile
http://au.linkedin.com/pub/jenni-gunter/21/134/966

Qualifications

  • PhD, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University, 2005
  • BSc (Hons) Biomedical Science, University of Technology, Sydney, 1999

Biography

Dr Gunter is an early career researcher at the APCRC-Q. She has a metabolic research background spanning almost 10 years. She completed her PhD in 2005 at the Oxford Centre for Diabetes, Endocrinology and Metabolism at Oxford University in lipid metabolism in islet cell biology related to type 2 diabetes and the emerging 'lipotoxicity' hypothesis and published peer reviewed articles and a book chapter on metabolic dysregulation in obesity. She was awarded a 3 year University of Queensland Postdoctoral Fellowship in 2006 to investigate adipocyte biology at the UQ Diamantina Institute. During this time, she secured grants from Diabetes Australia Research Trust (2008) and the PA Foundation (2008).

In 2009, Dr Gunter joined the APCRC-Q to research the intersection between chronic metabolic disorders and their emerging relationship to prostate cancer. She has co-authored papers demonstrating links between elevated insulin and related growth factors, associated with androgen deprivation and prostate cancer progression (Lubik, Gunter, Hollier... Herington, Gleave, Nelson, IGF-2 increases de novo steroidogenesis in prostate cancer cells, Endocrine-Related Cancer, 2013; Lubik, Gunter,...,Herington, Gleave, Nelson, Insulin increases de novo steroidogenesis in prostate cancer cells, Cancer Research, 2011) and two invited reviews, expanding this hypothesis (Gunter, Lubik,..., Nelson, The interactions between insulin and androgens in progression to CRPC, Advances in Urology, 2012; Gunter,.... Nelson, New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication Journal of Cell Biology, 2013). In 2013 she was awarded one of two 3 year PCFA Movember/Cure Cancer Australia Young Investigator Fellowships.

 

      Awards and grants

      Awards

      2013-2015 PCFA Movember/Cure Cancer Australia Young Investigator Fellowship
      2008 PAH Society Young Investigator Award (Higher Degree Scholar) Finalist
      2007 PAH Society Young Investigator Award (Higher Degree Scholar) Finalist
      1999 Awarded a place on the Faculty of Science Dean's Merit List for Academic Excellence

      Grants

      2008 Diabetes Australia Research Trust Grant Gunter J, Moffitt, Whitehead
      2008 PA Foundation Research Grant (Metabolic Program) Gunter J
      2006-2008 UQ Postgraduate Fellowship Gunter J

        Research interests

        metabolic syndrome, Insulin resistance, androgen deprivation therapy (ADT)

        Current research projects

        Therapeutics

        • Development of therapeutics for castrate resistant prostate cancer - targeting androgen synthesis in the prostate and the role of insulin

        Top publications

        • Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The interactions between insulin and androgens in progression to castrate resistant prostate cancer. Advances in Urology. 2011; (in press)
        • Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Research. 2011; 71(17):5754-64.
        • Su H, Gunter JH, de Vries M, Connor T, Wanyonyi S, Newell FS, Segal D, Molero JC, Reizes O, Prins JB, Hutley LJ, Walder K, Whitehead JP. Inhibition of inosine monophosphate dehydrogenase reduces adipogenesis and diet-induced obesity. Biochem Biophys Res Commun. 2009; 386(2):351-5.
        • Gunter JH, Thomas EC, Lengefeld N, Kruger SJ, Worton L, Gardiner EM, Jones A, Barnett NL, Whitehead JP. Characterisation of inosine monophosphate dehydrogenase expression during retinal development: differences between variants and isoforms. Int J Biochem Cell Biol. 2008; 40(9):1716-28.
        • Moffitt JH, Fielding BA, Evershed R, Berstan R, Currie JM, Clark A. Adverse physicochemical properties of tripalmitin in beta cells lead to morphological changes and lipotoxicity in vitro. Diabetologia. 2005; 48(9):1819-29.
        More publications are available on PubMed